SlideShare a Scribd company logo

AERD: Diagnosis and Treatment

•
•
K
KSAAI

Presentation by Dr. Donald Stevenson Kentucky Society of Allergy, Asthma & Clinical Immunology Annual Meeting-September 2011

Health & Medicine
1 of 56
Diagnosis and treatment of aspirin exacerbated respiratory disease (AERD) Donald D. Stevenson, MD Div: Allergy, Asthma and Immunology Scripps Clinic and the Scripps Research Institute La Jolla, California 858-764-9010 Fax 858-764-9011 E-Mail: [email_address]
Case #1 ,[object Object],[object Object],[object Object],[object Object],[object Object]
What is Aspirin- Exacerbated Respiratory Disease? ,[object Object],[object Object],[object Object],[object Object],[object Object]
AERD vs. Samter’s triad ,[object Object],[object Object],[object Object],[object Object]
AERD Population ,[object Object],[object Object],[object Object],[object Object],32 yo male anosmia, nasal congestion, nasal polyps. and asthma He is atopic and receiving Immunotherapy with partial improvement
ASA/NSAID reactions ONSET AERD: CHES + polyps Upper Airway Disease Only ASTHMA Mild intermittent Mild persistent Moderate persistent Severe persistent 1-2 URIs per yr Allergic Rhinitis Asthma: Provoking factors Age 30 yrs
Is AERD one disease or multiple pathological defects: many diseases? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
IL-4, IL-5, GM-CSF ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Deficiency of PGE 2 in AERD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
Bronchial ASA-lysine challenges induce LTC 4 synthesis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Szczeklik, A et al Am J Respir Crit Care Med 1996; 154:1608-14
Szczeklik, A et al Am J Respir Crit Care Med 1996; 154:1608 -14
Association of urine LTE 4 with severity of ASA induced bronchospasm ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Daffern, P et al JACI 104:559-64, 1999
 
 
The problem of diagnosing AERD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
243 patients presenting for OAC ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Dursun AB et al Predicting outcomes of OAC. Annals of Allergy, Asthma and Immunology 2008;100:420-25
Probability that patients have + OAC and AERD based on the severity of their historical reaction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Dursun B et al Predicting outcomes of OAC. Annals Allergy Asthma and Immunology 2008;100:420-25
Problems in diagnosing AERD by relying on history of ASA associated with asthma attack ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Relationship between historical ASA/NSAIDs -induced asthma attacks and the degree of bronchospasm during oral aspirin challenges ,[object Object],[object Object],[object Object],[object Object],[object Object],Williams AN, Simon RA, Stevenson DD JACI 2007; 120: 273-7
Results of OAC challenges n = 210 GI reactions 49 (23%), Cutaneous 20 (10%), laryngeal 16 (8%) Type of respiratory reactions n (%) Bronchial reactions: FEV1 106 (50%) 10-15% 32 (15%) 15-20 % 27 (13%) 21-30% 28 (13%) > 30% 19 (9%) All naso-ocular reactions naso-ocular ( FEV1< 10%) 188 (90%) 104 (50%)
Relationship between historical ASA-induced asthma reactions and oral ASA challenges n = 210 Williams, AN et al JACI 2007;120:273-7 OAC Respiratory Reactions Home N = 63 ER N = 101 Hospital N = 46 Naso-ocular and < 20 % FEV1 53 (84%) 79 (78%) 31 (67%) 21-30% FEV1 5 (8%) 14 (14%) 9 (20%) > 30% FEV1 5 (8%) 8 (8%) 6 (13%) Statistics Fishers Ex Chi Square p = NS
Reasons for the differences in degree of the asthmatic reactions between: Historical vs. OAC ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pros and Cons of ICU Challenges and Desensitization in AERD patients ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment of AERD ,[object Object],[object Object],[object Object]
Medical Treatment of AERD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment of AERD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Plasma Histamine in asthmatics: 1975 -1979 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
1979-80: ASA desensitization Rx ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Stevenson DD, Simon RA, Mathison DA, JACI 1980;66:82
Features of ASA desensitization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Scripps ASA desensitization and daily ASA: studies demonstrating therapeutic efficacy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
Polyp sinus surgery before and after ASA desensitization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Study of ASA desensitization treatment 1995-2000: 1-5 year follow-up ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Berges-Gimeno MP, Simon RA, Stevenson DD JACI 2003;111:180-6
Treatment of AERD continued ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ends: age 82 yrs AERD Dx 1984 ASA desen in 1984 325 mg BID x 27 yr Non-atopic Anosmia persists Asthma persists Rare infections Nasal congestion is Gone and no further polyps DC prednisone in 1984. Continues nasal and inhal. steroids
Ketorolac modified OAC ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ketorolac (cont # 2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Lee, RU et al Ann Allergy Asthma Immunol 2010;105:130-35
Ketorolac (cont #3) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Day 1 8 AM 8:30 9 :00 9:30 10:30 11:00 12 Noon 1:30 2 PM 5 PM Day 2 8 AM 11:00 2 PM 5 PM
[object Object],* 2 sample t test X2 was used to test categorical variables (1 yes and o no) Positive respiratory challenges Keto + ASA n = 82 OAC n = 92 P value* PNIF mean % decrease (SD) 28.7 (20.3) NA NA FEV1 mean % decrease (SD) 8.5 (12.2) 13.4 (12.4) .01 Duration, mean (SD) days 1.9 (0.42) 2.6 (0.64) <0.001 Duration < 2 days No (%) 68 (83%) 18 (20%) <0.001 Naso-ocular reaction only Number (%) 54 (65%) 35 (38%) <0.001
Types of bronchial and Extra-pulmonary reactions X 2 was used to test categorical variables (1 yes and o no) Reaction Keto + ASA n =82 OAC n =92 P values* Bronchial ( FEV1 > 15%) 26 (32%) 35 (38%) 0.61 15 -19% 11 (13%) 12 (13%) 0.66 20-29% 8 (10%) 13 (14%) 0.63 > 30% 7 (9%) 10(11%) 0.45 Extra Pulmonary reactions 19 (23%) 42 (45%) 0.002 Laryngeal 6 (7%) 17 (19%) 0.02 Gastrointestinal 10 (12%) 30 (33%) .001 Cutaneous 5 (6%) 9 (10%) 0.78
Mechanisms of ASA desensitization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Sousa et al (#3) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Sousa, A et al NEJM 2002; 347: 1493-9
Sousa, A et al NEJM 2002; 347: 1493-9 % of CD45+ leukocytes cysLT 1 receptors Baseline to 2 weeks Lysine ASA p = 0.008 Placebo p = 0.68 Baseline to 6 months Lysine ASA p = 0.02 Placebo p = 0.89 LTB 4 receptors
Sousa et al (conclusions) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
In vitro cellular changes: IL-4 and IL-13 induced signal transduction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Perez, GM et al J Immunol 168:1428, 2002
Does IL-4 cause AERD ? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Selective inhibition of IL-4 gene expression in human T-cells by Salicylates but not NSAIDs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cianferoni, A Casolaro, V et al Blood 2001;97:1742-49
Suppression of IL-4 during aspirin desensitization treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Katial RK et al JACI 2010; 126:738-44
 
Katial et al (cont.) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Katial RK et al JACI 2010;126:738-44
 

Recommended

Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Severe asthma
Severe asthmaSevere asthma
Severe asthma
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitisChulalongkorn Allergy and Clinical Immunology Research Group
 
Community Acquired Pneumonia
Community Acquired PneumoniaCommunity Acquired Pneumonia
Community Acquired Pneumonia
Ankur Gupta
 
Upper respiratory infections in children
Upper respiratory infections in childrenUpper respiratory infections in children
Upper respiratory infections in children
Khaled Saad
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitis
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Acute Pharyngitis
Acute PharyngitisAcute Pharyngitis
Acute Pharyngitis
SCGH ED CME
 
Fever of unkown origin
Fever of unkown originFever of unkown origin
Fever of unkown origin
ikramdr01
 

Recommended

Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Severe asthma
Severe asthmaSevere asthma
Severe asthma
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitisChulalongkorn Allergy and Clinical Immunology Research Group
 
Community Acquired Pneumonia
Community Acquired PneumoniaCommunity Acquired Pneumonia
Community Acquired Pneumonia
Ankur Gupta
 
Upper respiratory infections in children
Upper respiratory infections in childrenUpper respiratory infections in children
Upper respiratory infections in children
Khaled Saad
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitis
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Acute Pharyngitis
Acute PharyngitisAcute Pharyngitis
Acute Pharyngitis
SCGH ED CME
 
Fever of unkown origin
Fever of unkown originFever of unkown origin
Fever of unkown origin
ikramdr01
 
fever of unknown origin
fever of unknown originfever of unknown origin
fever of unknown origin
akifab93
 
Pyrexia of unknown origin
Pyrexia of unknown originPyrexia of unknown origin
Pyrexia of unknown origin
KAVI PRIYA
 
Fever Of Unknown Origin
Fever Of Unknown OriginFever Of Unknown Origin
Fever Of Unknown Origin
Prof. Dr. Aswinikumar Surendran
 
Hypersensitivity Pneumonitis
Hypersensitivity PneumonitisHypersensitivity Pneumonitis
Hypersensitivity PneumonitisChulalongkorn Allergy and Clinical Immunology Research Group
 
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Riaz Rahman
 
Aspirin exacerbated respiratory disease
Aspirin exacerbated respiratory diseaseAspirin exacerbated respiratory disease
Aspirin exacerbated respiratory disease
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Pediatric Sinusitis
Pediatric SinusitisPediatric Sinusitis
Pediatric Sinusitisshabeel pn
 
Massive hemoptysis
Massive hemoptysisMassive hemoptysis
Massive hemoptysisgagsol
 
Pneumonia
PneumoniaPneumonia
Pneumonia
doktorfattah hamzah
 
Allergic rhinitis
Allergic rhinitisAllergic rhinitis
Allergic rhinitis
Chulalongkorn Allergy and Clinical Immunology Research Group
 
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic AlveolitisFlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
Hazem Ali
 
Hemoptysis
HemoptysisHemoptysis
HemoptysisPratik Kumar
 
classification of pnemonia
classification of pnemoniaclassification of pnemonia
classification of pnemonia
Dr Harikrishna Harindran
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitis
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Asthma phenotypes
Asthma phenotypesAsthma phenotypes
Asthma phenotypesHiba Ashibany
 
Acute asthma what is new?
Acute asthma what is new?Acute asthma what is new?
Acute asthma what is new?
Dr.Venugopalan Poovathum Parambil
 
Anaphylaxis, acute allergic reactions, and angioedema
Anaphylaxis, acute allergic reactions, and angioedemaAnaphylaxis, acute allergic reactions, and angioedema
Anaphylaxis, acute allergic reactions, and angioedemaPaleenui Jariyakanjana
 
Croup in children
Croup in childrenCroup in children
Croup in children
Dr. Saad Saleh Al Ani
 
Acute epiglottitis
Acute epiglottitisAcute epiglottitis
Acute epiglottitisNandinii Ramasenderan
 
Asthma
AsthmaAsthma
Asthma
Dr. Arun Mathai Mani
 
Asthma- Targeted therapies | Jindal Chest Clinic
Asthma- Targeted therapies | Jindal Chest ClinicAsthma- Targeted therapies | Jindal Chest Clinic
Asthma- Targeted therapies | Jindal Chest Clinic
Jindal Chest Clinic
 
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
Asmallergie
 

More Related Content

What's hot

fever of unknown origin
fever of unknown originfever of unknown origin
fever of unknown origin
akifab93
 
Pyrexia of unknown origin
Pyrexia of unknown originPyrexia of unknown origin
Pyrexia of unknown origin
KAVI PRIYA
 
Fever Of Unknown Origin
Fever Of Unknown OriginFever Of Unknown Origin
Fever Of Unknown Origin
Prof. Dr. Aswinikumar Surendran
 
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Riaz Rahman
 
Aspirin exacerbated respiratory disease
Aspirin exacerbated respiratory diseaseAspirin exacerbated respiratory disease
Aspirin exacerbated respiratory disease
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Pediatric Sinusitis
Pediatric SinusitisPediatric Sinusitis
Pediatric Sinusitisshabeel pn
 
Massive hemoptysis
Massive hemoptysisMassive hemoptysis
Massive hemoptysisgagsol
 
Pneumonia
PneumoniaPneumonia
Pneumonia
doktorfattah hamzah
 
Allergic rhinitis
Allergic rhinitisAllergic rhinitis
Allergic rhinitis
Chulalongkorn Allergy and Clinical Immunology Research Group
 
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic AlveolitisFlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
Hazem Ali
 
classification of pnemonia
classification of pnemoniaclassification of pnemonia
classification of pnemonia
Dr Harikrishna Harindran
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitis
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Acute asthma what is new?
Acute asthma what is new?Acute asthma what is new?
Acute asthma what is new?
Dr.Venugopalan Poovathum Parambil
 
Anaphylaxis, acute allergic reactions, and angioedema
Anaphylaxis, acute allergic reactions, and angioedemaAnaphylaxis, acute allergic reactions, and angioedema
Anaphylaxis, acute allergic reactions, and angioedemaPaleenui Jariyakanjana
 
Croup in children
Croup in childrenCroup in children
Croup in children
Dr. Saad Saleh Al Ani
 

What's hot (20)

fever of unknown origin
fever of unknown originfever of unknown origin
fever of unknown origin
 
Pyrexia of unknown origin
Pyrexia of unknown originPyrexia of unknown origin
Pyrexia of unknown origin
 
Fever Of Unknown Origin
Fever Of Unknown OriginFever Of Unknown Origin
Fever Of Unknown Origin
 
Hypersensitivity Pneumonitis
Hypersensitivity PneumonitisHypersensitivity Pneumonitis
Hypersensitivity Pneumonitis
 
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
Diagnosis & Mangement of Community-Acquired Pneumonia, Hospital Acquired Pneu...
 
Aspirin exacerbated respiratory disease
Aspirin exacerbated respiratory diseaseAspirin exacerbated respiratory disease
Aspirin exacerbated respiratory disease
 
Pediatric Sinusitis
Pediatric SinusitisPediatric Sinusitis
Pediatric Sinusitis
 
Massive hemoptysis
Massive hemoptysisMassive hemoptysis
Massive hemoptysis
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Allergic rhinitis
Allergic rhinitisAllergic rhinitis
Allergic rhinitis
 
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic AlveolitisFlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
FlashPath - Lung - Hypersensitivity Pneumonitis - Extrinsic Allergic Alveolitis
 
Hemoptysis
HemoptysisHemoptysis
Hemoptysis
 
classification of pnemonia
classification of pnemoniaclassification of pnemonia
classification of pnemonia
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitis
 
Asthma phenotypes
Asthma phenotypesAsthma phenotypes
Asthma phenotypes
 
Acute asthma what is new?
Acute asthma what is new?Acute asthma what is new?
Acute asthma what is new?
 
Anaphylaxis, acute allergic reactions, and angioedema
Anaphylaxis, acute allergic reactions, and angioedemaAnaphylaxis, acute allergic reactions, and angioedema
Anaphylaxis, acute allergic reactions, and angioedema
 
Croup in children
Croup in childrenCroup in children
Croup in children
 
Acute epiglottitis
Acute epiglottitisAcute epiglottitis
Acute epiglottitis
 
Asthma
AsthmaAsthma
Asthma
 

Similar to AERD: Diagnosis and Treatment

Asthma- Targeted therapies | Jindal Chest Clinic
Asthma- Targeted therapies | Jindal Chest ClinicAsthma- Targeted therapies | Jindal Chest Clinic
Asthma- Targeted therapies | Jindal Chest Clinic
Jindal Chest Clinic
 
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
Asmallergie
 
Azithromycin and asthma
Azithromycin and asthmaAzithromycin and asthma
Azithromycin and asthmacscoville
 
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...
Juan Carlos Ivancevich
 
Aspergillosis Patients Support Outreach Meeting London June 2011 - David Denning
Aspergillosis Patients Support Outreach Meeting London June 2011 - David DenningAspergillosis Patients Support Outreach Meeting London June 2011 - David Denning
Aspergillosis Patients Support Outreach Meeting London June 2011 - David Denning
Graham Atherton
 
Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...
Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...
Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...
Saleem Hamilah , RCP , MsRC
 
Asthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptx
Asthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptxAsthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptx
Asthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptx
Saleem Hamilah , RCP , MsRC
 
asthmatalkforobgyn-091129130347-phpapp02.ppt
asthmatalkforobgyn-091129130347-phpapp02.pptasthmatalkforobgyn-091129130347-phpapp02.ppt
asthmatalkforobgyn-091129130347-phpapp02.ppt
ahmedmnadr ebraheim
 
8.Asthma
8.Asthma8.Asthma
8.Asthmaghalan
 
Exercise-Induced Bronchoconstriction
Exercise-Induced BronchoconstrictionExercise-Induced Bronchoconstriction
Exercise-Induced Bronchoconstriction
Chulalongkorn Allergy and Clinical Immunology Research Group
 
NSAIDs/ASA hypersensitivity diagnostic tests
NSAIDs/ASA hypersensitivity diagnostic testsNSAIDs/ASA hypersensitivity diagnostic tests
NSAIDs/ASA hypersensitivity diagnostic tests
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Management Of Copd & Asthma
Management Of Copd & AsthmaManagement Of Copd & Asthma
Management Of Copd & AsthmaDang Thanh Tuan
 
Biologic Therapy
Biologic TherapyBiologic Therapy
Biologic Therapydrmomusa
 
New asthma ppp modified 2011
New asthma ppp modified 2011New asthma ppp modified 2011
New asthma ppp modified 2011JohnScreen
 
Asthma Talk For Obgyn
Asthma Talk For ObgynAsthma Talk For Obgyn
Asthma Talk For Obgyn
University of Tennessee Memphis Obstetrics and Gyncology
 
Asthma attack reatment abreviated
Asthma attack reatment abreviatedAsthma attack reatment abreviated
Asthma attack reatment abreviated
MohamedKhamis77
 
20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab
20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab
20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab
Asmallergie
 

Similar to AERD: Diagnosis and Treatment (20)

Asthma- Targeted therapies | Jindal Chest Clinic
Asthma- Targeted therapies | Jindal Chest ClinicAsthma- Targeted therapies | Jindal Chest Clinic
Asthma- Targeted therapies | Jindal Chest Clinic
 
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
20171111 - Incorvaia - Immunoterapia con NPP e disease modifying
 
Azithromycin and asthma
Azithromycin and asthmaAzithromycin and asthma
Azithromycin and asthma
 
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...
 
Aspergillosis Patients Support Outreach Meeting London June 2011 - David Denning
Aspergillosis Patients Support Outreach Meeting London June 2011 - David DenningAspergillosis Patients Support Outreach Meeting London June 2011 - David Denning
Aspergillosis Patients Support Outreach Meeting London June 2011 - David Denning
 
Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...
Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...
Asthma Part 2 - Diagnosis, Evaluation, Phenotypes, Occupational Asthma_Khuran...
 
Asthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptx
Asthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptxAsthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptx
Asthma Part 1 - Definition, Epidemiology and Pathophysiology_Khurana.pptx
 
9 asthma
9 asthma9 asthma
9 asthma
 
asthmatalkforobgyn-091129130347-phpapp02.ppt
asthmatalkforobgyn-091129130347-phpapp02.pptasthmatalkforobgyn-091129130347-phpapp02.ppt
asthmatalkforobgyn-091129130347-phpapp02.ppt
 
8.Asthma
8.Asthma8.Asthma
8.Asthma
 
8
88
8
 
Exercise-Induced Bronchoconstriction
Exercise-Induced BronchoconstrictionExercise-Induced Bronchoconstriction
Exercise-Induced Bronchoconstriction
 
NSAIDs/ASA hypersensitivity diagnostic tests
NSAIDs/ASA hypersensitivity diagnostic testsNSAIDs/ASA hypersensitivity diagnostic tests
NSAIDs/ASA hypersensitivity diagnostic tests
 
Management Of Copd & Asthma
Management Of Copd & AsthmaManagement Of Copd & Asthma
Management Of Copd & Asthma
 
Biologic Therapy
Biologic TherapyBiologic Therapy
Biologic Therapy
 
New asthma ppp modified 2011
New asthma ppp modified 2011New asthma ppp modified 2011
New asthma ppp modified 2011
 
Asthma Talk For Obgyn
Asthma Talk For ObgynAsthma Talk For Obgyn
Asthma Talk For Obgyn
 
Asthma attack reatment abreviated
Asthma attack reatment abreviatedAsthma attack reatment abreviated
Asthma attack reatment abreviated
 
20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab
20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab
20181110 - Conte - Un altro farmaco biologico “in coming”: Benralizumab
 
Case Study
Case Study Case Study
Case Study
 

More from KSAAI

Sublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical ConsiderationsSublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical Considerations
KSAAI
 
New You Can Use: JCAAI Update
New You Can Use: JCAAI UpdateNew You Can Use: JCAAI Update
New You Can Use: JCAAI Update
KSAAI
 
Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...
Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...
Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...KSAAI
 
Allergy ABAI MOC Update-2011
Allergy ABAI MOC Update-2011Allergy ABAI MOC Update-2011
Allergy ABAI MOC Update-2011
KSAAI
 
SEAAI New News Presentation
SEAAI New News PresentationSEAAI New News Presentation
SEAAI New News Presentation
KSAAI
 
KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...
KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...
KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...
KSAAI
 
2009 Financial Survey Results
2009 Financial Survey Results 2009 Financial Survey Results
2009 Financial Survey Results KSAAI
 

More from KSAAI (7)

Sublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical ConsiderationsSublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical Considerations
 
New You Can Use: JCAAI Update
New You Can Use: JCAAI UpdateNew You Can Use: JCAAI Update
New You Can Use: JCAAI Update
 
Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...
Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...
Subcutaneous Immunotherapy: Is it Worth a Shot? Cost-effectiveness of Allerge...
 
Allergy ABAI MOC Update-2011
Allergy ABAI MOC Update-2011Allergy ABAI MOC Update-2011
Allergy ABAI MOC Update-2011
 
SEAAI New News Presentation
SEAAI New News PresentationSEAAI New News Presentation
SEAAI New News Presentation
 
KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...
KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...
KMA Annual Meeting 2010 - Allergy - Wheeze, Crackle, POP: When its not Asthma...
 
2009 Financial Survey Results
2009 Financial Survey Results 2009 Financial Survey Results
2009 Financial Survey Results
 

Recently uploaded

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
SwisschemDerma
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
Dr. Rabia Inam Gandapore
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
SwastikAyurveda
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
Suraj Goswami
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 

Recently uploaded (20)

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 

AERD: Diagnosis and Treatment

  • 1. Diagnosis and treatment of aspirin exacerbated respiratory disease (AERD) Donald D. Stevenson, MD Div: Allergy, Asthma and Immunology Scripps Clinic and the Scripps Research Institute La Jolla, California 858-764-9010 Fax 858-764-9011 E-Mail: [email_address]
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. ASA/NSAID reactions ONSET AERD: CHES + polyps Upper Airway Disease Only ASTHMA Mild intermittent Mild persistent Moderate persistent Severe persistent 1-2 URIs per yr Allergic Rhinitis Asthma: Provoking factors Age 30 yrs
  • 7.
  • 8.
  • 9.
  • 10.  
  • 11.  
  • 12.
  • 13. Szczeklik, A et al Am J Respir Crit Care Med 1996; 154:1608 -14
  • 14.
  • 15.  
  • 16.  
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Results of OAC challenges n = 210 GI reactions 49 (23%), Cutaneous 20 (10%), laryngeal 16 (8%) Type of respiratory reactions n (%) Bronchial reactions: FEV1 106 (50%) 10-15% 32 (15%) 15-20 % 27 (13%) 21-30% 28 (13%) > 30% 19 (9%) All naso-ocular reactions naso-ocular ( FEV1< 10%) 188 (90%) 104 (50%)
  • 23. Relationship between historical ASA-induced asthma reactions and oral ASA challenges n = 210 Williams, AN et al JACI 2007;120:273-7 OAC Respiratory Reactions Home N = 63 ER N = 101 Hospital N = 46 Naso-ocular and < 20 % FEV1 53 (84%) 79 (78%) 31 (67%) 21-30% FEV1 5 (8%) 14 (14%) 9 (20%) > 30% FEV1 5 (8%) 8 (8%) 6 (13%) Statistics Fishers Ex Chi Square p = NS
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.  
  • 31.
  • 32.
  • 33.
  • 34.  
  • 35.  
  • 36.
  • 37.
  • 38.
  • 39. Ends: age 82 yrs AERD Dx 1984 ASA desen in 1984 325 mg BID x 27 yr Non-atopic Anosmia persists Asthma persists Rare infections Nasal congestion is Gone and no further polyps DC prednisone in 1984. Continues nasal and inhal. steroids
  • 40.
  • 41.
  • 42.
  • 43.
  • 44. Types of bronchial and Extra-pulmonary reactions X 2 was used to test categorical variables (1 yes and o no) Reaction Keto + ASA n =82 OAC n =92 P values* Bronchial ( FEV1 > 15%) 26 (32%) 35 (38%) 0.61 15 -19% 11 (13%) 12 (13%) 0.66 20-29% 8 (10%) 13 (14%) 0.63 > 30% 7 (9%) 10(11%) 0.45 Extra Pulmonary reactions 19 (23%) 42 (45%) 0.002 Laryngeal 6 (7%) 17 (19%) 0.02 Gastrointestinal 10 (12%) 30 (33%) .001 Cutaneous 5 (6%) 9 (10%) 0.78
  • 45.
  • 46.
  • 47. Sousa, A et al NEJM 2002; 347: 1493-9 % of CD45+ leukocytes cysLT 1 receptors Baseline to 2 weeks Lysine ASA p = 0.008 Placebo p = 0.68 Baseline to 6 months Lysine ASA p = 0.02 Placebo p = 0.89 LTB 4 receptors
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.  
  • 54.
  • 55.
  • 56.